TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* esophageal carcinoma~* Lewis Tanner procedure (median laparotomy and right thoracotomy)~Exclusion Criteria:~* younger than 18 years~* severe lung disease~* chronic renal insufficiency~* a physical status classification \> III on the American Society of Anesthesiologists (ASA) scale~* impossible to perform epidural catheter placement~* thoraco-phreno-laparotomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Restrictive group (Type: ACTIVE_COMPARATOR): Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
- Liberal group (Type: ACTIVE_COMPARATOR): Patients who received \> 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Test of Chamber Pressure to Divers and Chamber Attendants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, age 18 - 65 years~* Completion of medical history questionnaire without concerns identified for exposure to increased pressure~* Familiarity with atmospheric pressure change:~* Experienced and active hyperbaric chamber inside attendant: more than 50 hyperbaric compressions, with more than 4 have been in the last 4 months; or~* Experienced and active SCUBA diver: more than 20 lifetime compressed gas open water (not swimming pool) dives, with more than 10 in the last 12 months~* Able to equalize middle ear pressure easily~Exclusion Criteria:~* Pregnancy~* Known risk for barotrauma, as identified on the medical history questionnaire, such as:~* Recent (within 12 months) inner ear or sinus surgery~* Spontaneous pneumothorax~* Pulmonary cysts~* Emphysema~* Bullous lung disease~* Chronic obstructive pulmonary disease needing chronic active therapy~* Inability to tolerate chamber confinement or pressure~* Presence of heart failure~* Presence of any implanted electrical device, except hyperbaric-approved pacemakers~* Presence of middle-ear tympanostomy tubes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sea Level Equivalent 1.2 atm abs (air) (Type: SHAM_COMPARATOR): Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion
- Sea Level Equivalent 1.5 atm abs (O2) (Type: EXPERIMENTAL): Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion
- Altitude Equivalent 1.2 atm abs (air) (Type: SHAM_COMPARATOR): Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion
- Altitude Equivalent 1.5 atm abs (O2) (Type: EXPERIMENTAL): Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Azithromycin for the Treatment of Yaws

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All children 6 months to 15 years of age who present to LMC with suggestive skin lesions or joint pains and VDRL and TPHA testing are positive~* Suggestive skin lesions defined as: Symptomatic \> 4 weeks, painless, a traumatic ulcers with raised margins. VDRL positive when titer of at least 1:16~Exclusion Criteria:~* Pregnancy~* Less than 6 months of age~* Known allergy to penicillin or macrolide~* Use of antibiotics active against treponema during the preceding six months (penicillin-G-benzathine, ceftriaxone, azithromycin or doxycycline)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Penicillin-G-Benzathine (Type: ACTIVE_COMPARATOR): penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
- Azithromycin (Type: EXPERIMENTAL): Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be normal healthy adult volunteers (with no significant abnormalities in medical history, physical exam, vital signs or lab evaluations at screening) in order to be eligible to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A: SPD503 (4mg) (Type: ACTIVE_COMPARATOR): None
- B: VYVANSE (50mg) (Type: ACTIVE_COMPARATOR): None
- C: SPD503 (4mg) + VYVANSE (50mg) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria: participants with:~* A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 (with a unilateral score of at least 2 for each nostril) despite completion of a prior intranasal corticosteroid (INCS) treatment for at least 8 weeks before screening.~* Presence of at least two of the following symptoms prior to screening: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell.~Exclusion criteria:~* Participants \<18 or \>65 years of age.~* Sinonasal outcome test (SNOT-22) \<7.~* Participants who had taken other investigational drugs or prohibited therapy for this study within 2 months before screening or 5 half-lives, whichever was longer:~  * Burst of systemic corticosteroids within the 2 months before screening or were scheduled to receive systemic corticosteroids during the study period for another condition~ * INCS drops within 1 month prior to screening~ * Monoclonal antibody (mAB) and immunosuppressive treatment~ * Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days of Visit 1~ * Leukotriene antagonists/modifiers unless participant was on a continuous treatment for at least 30 days prior to Visit 1.~* Participants who had undergone any nasal surgery (including polypectomy) within 6 months before screening or have had more than 5 sinonasal surgeries in the past of which maximal 2 were surgeries changing the lateral wall structure of the nose.~* Participants with asthma having:~  * Forced Expiratory Volume (FEV1) ≤ 60%, or .Asthma exacerbation requiring systemic (oral and/or parenteral) steroid treatment or hospitalization for \>24 hours for treatment of asthma, within 3 months prior to screening or were on a dose of greater than 1000 microgram (mcg) fluticasone or an equivalent INCS.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
- Dupilumab 300 mg QW (Type: EXPERIMENTAL): Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
The following eligibility criteria pertain to patients enrolling into PART 2 of the study:~Inclusion:~* Have a histologically confirmed diagnosis of high grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer~* Received at least 3 prior chemotherapy regimens. Non-chemotherapy regimens and maintenance therapies administered as single agent treatment will not count as a chemotherapy regimen~* Relapsed/progressive disease as confirmed by CT scan~* Have biopsiable and measurable disease. Note: biopsy is optional for patients known to harbor a deleterious gBRCA mutation~* Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses~Exclusion:~* History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed \>6 months prior and/or bone marrow transplant \>2 years prior to first dose of rucaparib).~* Prior treatment with any PARP inhibitor~* Symptomatic and/or untreated central nervous system metastases~* Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib~* Hospitalization for bowel obstruction within 3 months prior to enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ovarian cancer (Type: EXPERIMENTAL): rucaparib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of hypertension~* Clinical diagnosis of one or more risk factors, such as diabetes, smoking habit, lipid metabolism abnormality, history of ischemic heart disease (IHD) or cerebrovascular disease, obesity (BMI\>25), chronic heart failure (NYHA II-III), and electrocardiogram (ECG) abnormality (LVH)~Exclusion Criteria:~* Patients who have already been administered ARB~* Patients with IHD within 6 months after percutaneous coronary intervention(PCI), and who are stable but are going to implement PCI or coronary artery bypass grafting(CABG)~* Severe/malignant/secondary hypertensive patients~* Pregnant women and women of childbearing potential~* History of heart failure, unstable angina, myocardial infarction, PTCA, or CABG within the preceding 6 months~* Arrhythmia needed to be treated or accompanied with symptoms, second or third degree AV block~* Severe renal impairment (Serum creatinine \>3.0 mg/dl)~* Severe hepatic impairment (Hepatic failure, Cirrhosis, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Non-ARB (Type: ACTIVE_COMPARATOR): 'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
- Valsartan (Type: EXPERIMENTAL): Valsartan add-on treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Maximum IMT \>1.2 mm and 3.5 mm at any location in the carotid ultrasound studies conducted at both Visit 2 (Week -4) and Visit 3 (Week -2)~* Subjects with age and no other risk factor: Fasting LDL-C at Visit 1 (Week -6) is \>120 mg/dL (3.1mmol/L) and \<190 mg/dL (4.9 mmol/L)~* Subjects with 2 or more risk factors and a 10-year coronary heart disease (CHD) risk \< 10%: Fasting LDL-C at Visit 1 (Week -6) is \>120 mg/dL (3.1 mmol/L) and \<160 mg/dL (4.1 mmol/L)~Exclusion Criteria:~* Use of pharmacologic lipid-lowering medications (eg, HMG-CoA reductase inhibitors, fibrate derivatives, bile acid binding resins, niacin or its analogues at doses \>400 mg) within 12 months prior to Visit 1 (Week -6).~* Clinical evidence of coronary artery disease or any other atherosclerotic disease such as angina, MI, TIA, symptomatic carotid artery disease, CVA, CABG, PTCA, peripheral arterial disease, AAA.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study related procedures~* Inoperable, Gastro-Entero-Pancreatic-Neuroendocrine Tumour G1 or G2 (Proliferation Index, Ki67-Index: 0 to ≤20%) confirmed by pathological/histological assessment~* Progressive disease within 12 months before inclusion (RECIST 1.1: increase of \>20% tumour load; by Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)~* Measurable disease according to RECIST 1.1.~* Metastatic disease confirmed by CT/MRI.~* Functioning or non-functioning NET (G1, G2).~* Positive Octreo-Scan (≥ Grade 2 Krenning scale) or positive DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-TATE (Tyr3-Thre8-Octreotide or DOTA-Tyr3-octreotate)/TOC (Tyr3-octreotide) -PET (Positron-Emission-Tomography) -CT within 12 months prior to screening~Exclusion Criteria:~* Has the diagnosis of Insulinoma~* Has a diagnosis of a multiple endocrine neoplasia (MEN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lanreotide Autogel 120mg & Temozolomide (Type: EXPERIMENTAL): Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female subjects aged between and including, 10 to 25 years at the time of the first vaccination.~* Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for vaccination visits etc) should be enrolled in the PMS.~* Written informed consent obtained from the subject or the subjects' parent/ guardian.~* Subjects of childbearing potential must not be pregnant. Absence of pregnancy should be verified (e.g. urine pregnancy test) as per the investigator's clinical judgement.~* Subjects with no contraindication according to the local approved prescribing information.~* No previous administration of an HPV vaccine other than Cervarix®.~* No previous administration of more than two doses of Cervarix®.~* No planned administration of an HPV vaccine other than Cervarix® during the PMS

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: None): Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adenocarcinoma of the pancreas~* no prior chemo except adjuvant~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1~* peripheral neuropathy \</= Gr. 1~Exclusion Criteria:~* Pregnant/lactating females~* Uncontrolled heart disease, diabetes, psychiatric disorder~* Therapeutic doses of Warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- capecitabine, docetaxel, gemcitabine (Type: EXPERIMENTAL): Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled GM-CSF Therapy of Autoimmune PAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female of male 18 years of age or older~* Diagnosis of autoimmune PAP~* Able and willing to provide written informed consent~* Eligible for whole lung lavage determined as the presence of persistent or progressive respiratory failure (PaO2 at rest \< 60 mm Hg) or desaturation \< 90% or \> 5 percentage points during standard exercise~Exclusion Criteria:~* Diagnosis with secondary PAP, congenital PAP, or hereditary PAP~* Contraindication to whole lung lavage~* Contraindication to administration of inhaled GM-CSF~* Chronic lung disease associated with already existing respiratory failure, such as emphysema or pulmonary fibrosis, chronic heart failure, ischemic heart disease, active pulmonary embolism, progressive cancer, and other severe metabolic conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GM-CSF Group (Type: EXPERIMENTAL): Scheduled Baseline WLL: All participants will receive scheduled bilateral WLL at baseline (month 0).~GM-CSF induction treatment: All participants will receive inhaled GM-CSF (250 mcg daily, 7 consecutive days every other week for 12 weeks beginning 1 week after the scheduled baseline WLL).~Washout period: All participants will not receive inhaled GM-CSF treatment for 4 weeks immediately following GM-CSF induction treatment.~GM-CSF maintenance treatment: All participants will receive inhaled GM-CSF (250 mcg daily on days 1 and 3 of every consecutive 14-day period for 6 months beginning 17 weeks after the scheduled baseline WLL).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (PaO2 at rest \<60 mmHg of PaO2 \> 60 mmHg at rest AND desaturation \<90% at rest OR decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL.
- Control Group (Type: OTHER): Scheduled Baseline WLL: All participants will receive a scheduled bilateral WLL at baseline (month 0).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (defined by a resting PaO2 \<60 mmHg or \> 60 mmHg and desaturation \<90% at rest or decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete